Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study

Yaodan Bi,1,* Yingchao Zhu,2,* Shuai Tang1 1Department of Anesthesiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Anesthesiology, West China Hospital, Sichuan Univ...

Full description

Bibliographic Details
Main Authors: Bi Y, Zhu Y, Tang S
Format: Article
Language:English
Published: Dove Medical Press 2023-12-01
Series:Journal of Pain Research
Subjects:
Online Access:https://www.dovepress.com/therapeutic-potential-of-downregulated-interleukin-6-signaling-for-the-peer-reviewed-fulltext-article-JPR
_version_ 1797385663350308864
author Bi Y
Zhu Y
Tang S
author_facet Bi Y
Zhu Y
Tang S
author_sort Bi Y
collection DOAJ
description Yaodan Bi,1,* Yingchao Zhu,2,* Shuai Tang1 1Department of Anesthesiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shuai Tang, Department of anesthesiology, Peking Union Medical College Hospital, Beijing, People’s Republic of China, Email tangshuai@pumch.cnIntroduction: While numerous studies have emphasized the pivotal involvement of the Interleukin 6 (IL-6) pathway in the development of chronic pain, the causal nature of this relationship remains uncertain.Methods: In this study, we opted to include genetic variants situated within the locus of the IL-6 receptor (IL-6R) that exhibited associations with C-reactive protein (CRP) levels. CRP serves as a downstream effector in the IL-6 pathway. Utilizing these variants as genetic proxies, we aimed to modulate IL-6 signaling. Employing a two-sample Mendelian randomization (MR) approach, we investigated the potential link between the genetic proxy and seven distinct subtypes of chronic pain, categorized based on their corresponding body locations. Moreover, we examined the relationship between chronic pain and an alternative instrument of IL-6 signaling that was weighted based on s-IL-6R levels. Furthermore, we conducted exploratory analyses to estimate the plausible causal association between CRP, gp130, and the subtypes of chronic pain.Results: Our analysis showed that genetic proxied downregulation of IL-6 signaling, weighted on CRP levels, was linked to a reduced risk of chronic back and knee pain. The sensitivity analyses across various MR methods confirmed the consistency of the findings and showed no evidence of horizontal pleiotropy or heterogeneity. Moreover, the results remained robust with different sets of instrument variables. A genetically increased level of s-IL-6R was also negatively associated with chronic back and knee pain. However, there was no causal relationship between CRP and gp130 with chronic pain.Conclusion: Based on our findings, there is evidence to suggest a potential causal relationship between IL-6 signaling and chronic back and knee pain. Consequently, the downregulation of IL-6 signaling holds promise as a potential therapeutic target for addressing chronic back and knee pain.Keywords: IL-6 signaling, chronic pain, Mendelian randomization
first_indexed 2024-03-08T21:57:32Z
format Article
id doaj.art-e289b95355df4118b62ce1c48e19c7d7
institution Directory Open Access Journal
issn 1178-7090
language English
last_indexed 2024-03-08T21:57:32Z
publishDate 2023-12-01
publisher Dove Medical Press
record_format Article
series Journal of Pain Research
spelling doaj.art-e289b95355df4118b62ce1c48e19c7d72023-12-19T17:37:32ZengDove Medical PressJournal of Pain Research1178-70902023-12-01Volume 164317432889087Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization StudyBi YZhu YTang SYaodan Bi,1,* Yingchao Zhu,2,* Shuai Tang1 1Department of Anesthesiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shuai Tang, Department of anesthesiology, Peking Union Medical College Hospital, Beijing, People’s Republic of China, Email tangshuai@pumch.cnIntroduction: While numerous studies have emphasized the pivotal involvement of the Interleukin 6 (IL-6) pathway in the development of chronic pain, the causal nature of this relationship remains uncertain.Methods: In this study, we opted to include genetic variants situated within the locus of the IL-6 receptor (IL-6R) that exhibited associations with C-reactive protein (CRP) levels. CRP serves as a downstream effector in the IL-6 pathway. Utilizing these variants as genetic proxies, we aimed to modulate IL-6 signaling. Employing a two-sample Mendelian randomization (MR) approach, we investigated the potential link between the genetic proxy and seven distinct subtypes of chronic pain, categorized based on their corresponding body locations. Moreover, we examined the relationship between chronic pain and an alternative instrument of IL-6 signaling that was weighted based on s-IL-6R levels. Furthermore, we conducted exploratory analyses to estimate the plausible causal association between CRP, gp130, and the subtypes of chronic pain.Results: Our analysis showed that genetic proxied downregulation of IL-6 signaling, weighted on CRP levels, was linked to a reduced risk of chronic back and knee pain. The sensitivity analyses across various MR methods confirmed the consistency of the findings and showed no evidence of horizontal pleiotropy or heterogeneity. Moreover, the results remained robust with different sets of instrument variables. A genetically increased level of s-IL-6R was also negatively associated with chronic back and knee pain. However, there was no causal relationship between CRP and gp130 with chronic pain.Conclusion: Based on our findings, there is evidence to suggest a potential causal relationship between IL-6 signaling and chronic back and knee pain. Consequently, the downregulation of IL-6 signaling holds promise as a potential therapeutic target for addressing chronic back and knee pain.Keywords: IL-6 signaling, chronic pain, Mendelian randomizationhttps://www.dovepress.com/therapeutic-potential-of-downregulated-interleukin-6-signaling-for-the-peer-reviewed-fulltext-article-JPRil-6 signalingchronic painmendelian randomization
spellingShingle Bi Y
Zhu Y
Tang S
Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study
Journal of Pain Research
il-6 signaling
chronic pain
mendelian randomization
title Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study
title_full Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study
title_fullStr Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study
title_full_unstemmed Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study
title_short Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study
title_sort therapeutic potential of downregulated interleukin 6 signaling for the treatment of chronic pain a mendelian randomization study
topic il-6 signaling
chronic pain
mendelian randomization
url https://www.dovepress.com/therapeutic-potential-of-downregulated-interleukin-6-signaling-for-the-peer-reviewed-fulltext-article-JPR
work_keys_str_mv AT biy therapeuticpotentialofdownregulatedinterleukin6signalingforthetreatmentofchronicpainamendelianrandomizationstudy
AT zhuy therapeuticpotentialofdownregulatedinterleukin6signalingforthetreatmentofchronicpainamendelianrandomizationstudy
AT tangs therapeuticpotentialofdownregulatedinterleukin6signalingforthetreatmentofchronicpainamendelianrandomizationstudy